RxDoctor Payments Data

Kayvan Amini, DO

Cardiovascular Disease · Pembroke Pines, FLNPI 1124243563

Payments from drug & device makers

$5,588in general payments, 2019–2025

Across 80 payments — averaging $69.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Novartis$261
  • Gilead$205
  • Johnson & Johnson$204
  • Pfizer$171
  • Amgen$167
  • plus $418 from 12 others

What the payments were for

  • Consulting fees$2,79050%
  • Travel & lodging$77714%
  • Food & beverage$2,02136%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,588 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$270,123
Medicare patients
379
Services billed
2,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$53,856
FarxigaDapagliflozin Propanediol25$30,017
EntrestoSacubitril/Valsartan17$23,972
BrilintaTicagrelor27$23,137
XareltoRivaroxaban18$16,248
JardianceEmpagliflozin12$7,046
Metoprolol Succinate115$1,367
Ezetimibe31$1,274
Rosuvastatin Calcium61$1,214
Valsartan38$1,207
Atorvastatin Calcium102$928
Losartan Potassium35$399
Isosorbide Mononitrate ErIsosorbide Mononitrate33$372
ClopidogrelClopidogrel Bisulfate49$308
Amlodipine Besylate66$307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$171$53,85654 claims
AstraZenecaFarxiga, Brilinta$4,162$53,15452 claims
NovartisEntresto$261$23,97217 claims
Johnson & JohnsonXarelto$204$16,24818 claims
Boehringer IngelheimJardiance$32$7,04612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →